Showing 2441-2450 of 9131 results for "".
Cosmeceutical Options
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/cosmeceutical-options/18208/As the cosmeceutical market continues to grow, Nancy Samolitis, MD highlights one of her favorite options to support skin health.Cosmetic Boot Camp 2018 Presenter Insight
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/cosmetic-boot-camp-2018-presenter-insight/18290/Get up to date on Cosmetic Bootcamp. Presenters provide updates on microneedling, radiofrequency devices, lasers, fillers, neurotoxins, and more. The Cosmetic Bootcamp® provides training and educational opportunities for aesthetic medicine physicians and their staff. Hear from: Mary Lupo, MD; Vic NaEczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, andAubio Launches, Updates from Prescriber's Choice, BioPharmX
https://practicaldermatology.com/topics/practice-management/dermwiretv-aubio-launches-updates-from-prescriber-s-choice-biopharmx/18584/In this edition of DermWireTV, Aubio launches OTC treatment for cold sores with backing from Paul Mitchell partner. Prescriber's Choice facilitates in-office prescription dispensing. BioPharmX enrolls phase 2b trial for topical minocycline and Merz acquires ONLight Sciences, maker of PFD patch for tTarget: PASI 90
https://practicaldermatology.com/topics/psoriasis/target-pasi-90/18593/With new advancements in biologic therapy, patients are gaining more control of psoriasis. Whereas PASI 50 was once seen as a significant improvement, patients today can expect to achieve PASI 90. Can PASI 100 be far behind?Laser hair removal in darker skin types, challenges and technological advances for treatment
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-hair-removal-in-darker-skin-types-challenges-and-technological-advances-for-treatment/18800/Andrew Alexis, MD discusses laser hair removal treatment challenges in patients with higher Fitzpatrick skin types, and how recent advances in technology have been able to address these to deliver effective treatment with minimal pain.Improve Your Practice: Creating Innovation
https://practicaldermatology.com/topics/practice-management/improve-your-practice-creating-innovation/18649/Kathryn Schwarzenberger, MD and Tammie Ferringer, MD sat down with host Neal Bhatia, MD to discuss creativity and innovation in medicine. Based on a session they presented at the American Academy of Dermatology Annual Meeting, they offer tips for leaving time in your day to think about what you're dOvercoming Challenges in Topical Psoriasis Care
https://practicaldermatology.com/topics/psoriasis/overcoming-challenges-in-topical-psoriasis-care/18685/Jerry Bagel, MD and Neil J. Korman, MD discuss topical treatment options for palmar plantar psoriasis and the combined use of topical corticosteroids with phototherapy. They also address alternative topical agents like topical immunomodulators.Janssen Approvals, New Thermage FLX, Restylane Silk Cannulas
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-janssen-approvals-new-thermage-flx-restylane-silk-cannulas/18401/Janssen Biotech's Stelara is now approved for the treatment of adolescents 12 years of age or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Janssen's SIMPONI ARIA® cleared for the treatment of adults with active psoriatic arthritis or activeVitiligo Update: Pathogenesis, Therapies, and Integrative Approaches
https://practicaldermatology.com/issues/may-june-2025/vitiligo-update-pathogenesis-therapies-and-integrative-approaches/35920/Vitiligo is a chronic autoimmune condition characterized by depigmented white patches due to melanocyte destruction, attributed to genetic factors and environmental triggers.